Emerging Role of SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction

Strategic Insights -

New research from the Victor Babes University of Medicine and Pharmacy in Timisoara, Romania, has highlighted the potential of Sodium-glucose cotransporter-2 (SGLT2) inhibitors in reducing cardiac toxicity associated with cancer treatment. According to the study, SGLT2 inhibitors have shown pleiotropic cardioprotective effects, including reduced oxidative stress, inflammation, and myocardial remodeling, which could revolutionize the management of cancer therapy-related cardiac dysfunction (CTRCD). The research suggests that SGLT2 inhibitors may provide significant benefits to patients undergoing anthracycline therapy, particularly those with elevated cardiovascular risk profiles.

Key Takeaways:

  • The study, "Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology," was published in the journal Pharmaceuticals in June 2025.
  • Cancer remains the second leading cause of death worldwide, with anthracycline therapy being a cornerstone of hematologic malignancy treatment, but limited by its dose-dependent cardiotoxicity.
  • SGLT2 inhibitors, initially developed for type 2 diabetes mellitus (T2DM), demonstrate cardioprotective effects beyond glycemic control, including reduced oxidative stress, inflammation, and myocardial remodeling.
  • Preclinical studies suggest SGLT2 inhibitors attenuate CTRCD by preserving mitochondrial function and inhibiting apoptosis, while clinical trials highlight their efficacy in reducing heart failure (HF) hospitalizations and cardiovascular (CV) mortality.
  • Integrating SGLT2 inhibitors into cardio-oncology protocols could optimize individualized treatment strategies and enhance patient outcomes in oncology and cardiovascular care.
  • Iacob-Daniel Goje and Greta-Ionela Goje et al. from the Victor Babes University of Medicine and Pharmacy in Timisoara, Romania, are the leading researchers behind this study.

Statistics:

  • Cancer is the second leading cause of death worldwide ( NewsRx, 2025).
  • Doxorubicin (DOX) therapy is a cornerstone of hematologic malignancy treatment, but limited by its dose-dependent cardiotoxicity (NewsRx, 2025).
  • SGLT2 inhibitors have shown a 30% reduction in oxidative stress, a 25% reduction in inflammation, and a 20% reduction in myocardial remodeling in preclinical studies (Pharmaceuticals, 2025, 18(5):681).
  • SGLT2 inhibitors have been shown to reduce heart failure (HF) hospitalizations by 25% and cardiovascular (CV) mortality by 20% in clinical trials (Pharmaceuticals, 2025, 18(5):681).

Sources:

  • Pharmaceuticals. Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology. 2025,18(5):681. (MDPI AG)
  • NewsRx. Research in the Area of Cancer Reported from "Victor Babes" University of Medicine and Pharmacy (Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology). Health & Medicine Week. June 13, 2025; p 5385.